40608-76-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzyl-5-methoxy-1H-benzo[d]imidazole is utilized as a pharmaceutical agent for its demonstrated anti-cancer and anti-inflammatory properties. Its ability to exhibit cytotoxic effects against certain cancer cell lines positions it as a promising candidate for the development of novel anti-cancer drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Benzyl-5-methoxy-1H-benzo[d]imidazole serves as a valuable building block. Its unique structure allows for the creation of a variety of complex organic compounds, contributing to the advancement of chemical research and the discovery of new materials.
Used in Medicinal Chemistry:
2-Benzyl-5-methoxy-1H-benzo[d]imidazole is also employed in medicinal chemistry, where its biological activities are harnessed to design and develop new therapeutic agents. Its potential role in treating cancer and inflammatory conditions makes it a significant compound for further exploration and application in medicine.

Upstream product

• 96-96-8 4-methoxy-2-nitroaniline 
• 103-80-0 phenylacetyl chloride 
• 122-78-1 phenylacetaldehyde 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 14661-56-4 5-Methoxy-2-nitro-α-phenylacetanilid 
• 16133-49-6 5-methoxy-2-nitroaniline 
• 1272902-62-1 C₁₅H₁₆N₂O₂ 
• 2019-10-5 N-(4-methoxy-2-nitrophenyl) phenylacetamide 
• 103-82-2 phenylacetic acid 

Downstream Products

• 1370000-18-2 C₁₉H₂₁N₃O 
• 131336-23-7 2-benzyl-5⁽⁶⁾-hydroxybenzimidazole 

Relevant academic research and scientific papers

Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB

For finding the novel inhibitor of nuclear factor κB activity, a series of benzimidazole derivatives were rationally designed, synthesized and systematically studied for their in vitro activities against LPS induced NF-κB inhibition in RAW 264.7 cells using the SEAP assay based on the flexible chalcone JSH ((E)-1-(2-hydroxy-6-(isopentyloxy)phenyl)-3-(4-hydroxy phenyl)prop-2-en-1-one) which was previously reported. Although most of the benzimidazole derivatives showed strong inhibitory activity in low micromolar potency, 2-(4-methoxybenzyl)-1H-benzo[d]imidazole (3m; IC50 = 1.7 μM) and 2-(2-methoxybenzyl)-1H-benzo[d]imidazole (3n; IC50 = 2.4 μM) showed the best inhibition. The structure activity relationship revealed that 2-benzylbenzimidazole scaffold with hydrogen bonding acceptor on phenyl ring appears as a pharmacophore.

A novel series of benzimidazole NR2B-selective NMDA receptor antagonists

A series of novel benzimidazoles are discussed as NR2B-selective N-methyl-d-aspartate (NMDA) receptor antagonists. High throughput screening (HTS) efforts identified a number of potent and selective NR2B antagonists such as 1. Exploration of the substituents around the core of this template identified a number of compounds with high potency for NR2B (pIC50 >7) and good selectivity against the NR2A subunit (pIC50 2+ and radioligand binding studies. These agents offer potential for the development of therapeutics for a range of nervous system disorders including chronic pain, neurodegeneration, migraine and major depression.

Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to substituted 2-aryl-benzimidazoles.